KR950031059A - 골다공증 치료용 약제학적 조성물 - Google Patents

골다공증 치료용 약제학적 조성물 Download PDF

Info

Publication number
KR950031059A
KR950031059A KR1019950008333A KR19950008333A KR950031059A KR 950031059 A KR950031059 A KR 950031059A KR 1019950008333 A KR1019950008333 A KR 1019950008333A KR 19950008333 A KR19950008333 A KR 19950008333A KR 950031059 A KR950031059 A KR 950031059A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
active ingredient
treating osteoporosis
osteoporosis according
isoadfumulon
Prior art date
Application number
KR1019950008333A
Other languages
English (en)
Inventor
히로야스 도베
가즈유키 기타무라
Original Assignee
사토 미쓰아키
훽스트 저팬 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사토 미쓰아키, 훽스트 저팬 리미티드 filed Critical 사토 미쓰아키
Publication of KR950031059A publication Critical patent/KR950031059A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

본 발명은 활성 성분으로서 후물론, 코후물론, 애드후물론, 이소후물론, 이소코후물론, 및 이소애드후물론을 포함하는 그룹으로부터 선택된 하나 이상의 화합물 유효량과 약제학적으로 허용되는 담체 또는 부형제와의 배합물을 포함하는 골다공증 치료용 약제학적 조성물에 관한 것이다. 후물론, 코후물론, 애드후물론은 홉스로부터 추출된 성분인 α산에 속하는 화합물인 반면, 이소후물론, 이소코후물론 및 이소애드후물론은 α산의 이성체인 이소α산 유도체에 속하는 화합물이다.
상술한 화합물은 골 재흡수 억제 활성을 갖고 골다공증 치료에 유용하다.

Description

골다공증 치료용 약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 활성 성분으로서 후물론, 코후물론, 애드후물론, 이소후물론, 이소코후물론 및 이소애드후물론을 포함하는 그룹으로부터 선택된 하나 이상의 화합물 유효량과 약제학적으로 허용되는 담체 또는 부형제와의 배합물을 포함하는 골다공증 치료용 약제학적 조성물.
  2. 제1항에 있어서, 활성 성분으로서 후물론을 포함하는 골다공증 치료용 약제학적 조성물.
  3. 제1항에 있어서, 활성 성분으로서 코후물론을 포함하는 골다공증 치료용 약제학적 조성물.
  4. 제1항에 있어서, 활성 성분으로서 애드후물론을 포함하는 골다공증 치료용 약제학적 조성물.
  5. 제1항에 있어서, 활성 성분으로서 이소후물론을 포함하는 골다공증 치료용 약제학적 조성물.
  6. 제1항에 있어서, 활성 성분으로서 이소코후물론을 포함하는 골다공증 치료용 약제학적 조성물.
  7. 제1항에 있어서, 활성 성분으로서 이소애드후물론을 포함하는 골다공증 치료용 약제학적 조성물.
  8. 제1항에 있어서, 활성 성분으로서 후물론, 코후물론, 애드후물론, 이소후물론, 이소코후물론 및 이소애드후물론의 포함하는 골다공증 치료용 약제학적 조성물.
  9. 제1항에 있어서, 활성 성분으로서 홉스(hops)로부터 추출하여 수득한 후물론, 코후물론, 애드후물론, 이소후물론, 이소코후물론, 및 이소애드후물론의 혼합물을 포함하는 골다공증 치료용 약제학적 조성물.
  10. 제1항에 있어서, 활성 성분으로서 홉스로부터 추출하여 수득한 후물론, 코후물론 및 애드후물론을 포함하는 골다공증 치료용 약제학적 조성물.
  11. 제1항에 있어서, 활성 성분으로서 홉스로부터 추출하여 수득한 이소후물론, 이소코후물론, 및 이소애드후물론을 혼합물을 포함하는 골다공증 치료용 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950008333A 1994-04-12 1995-04-11 골다공증 치료용 약제학적 조성물 KR950031059A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7323094 1994-04-12
JP94-073230 1994-04-12

Publications (1)

Publication Number Publication Date
KR950031059A true KR950031059A (ko) 1995-12-18

Family

ID=13512179

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950008333A KR950031059A (ko) 1994-04-12 1995-04-11 골다공증 치료용 약제학적 조성물

Country Status (13)

Country Link
US (1) US5604263A (ko)
EP (1) EP0677289B1 (ko)
KR (1) KR950031059A (ko)
AT (1) ATE175575T1 (ko)
AU (1) AU696334B2 (ko)
CA (1) CA2146820A1 (ko)
DE (1) DE69507185T2 (ko)
DK (1) DK0677289T3 (ko)
ES (1) ES2129691T3 (ko)
FI (1) FI951702A (ko)
HU (1) HUT71604A (ko)
NO (1) NO951422L (ko)
TW (1) TW427901B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US7718198B2 (en) * 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US8168234B2 (en) * 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7666449B2 (en) * 2001-06-20 2010-02-23 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US20040219240A1 (en) * 2001-06-20 2004-11-04 Babish John G. Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US8142819B2 (en) 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7270835B2 (en) * 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7279185B2 (en) * 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US20090263522A1 (en) * 2001-10-26 2009-10-22 Babish John G Curcuminoid Compositions Exhibiting Synergistic Inhibition Of The Expression And/Or Activity Of Cyclooxygenase-2
US8158160B2 (en) 2001-11-13 2012-04-17 Eric Hauser Kuhrts Anti-inflammatory cyclooxygenase inhibitors
KR100993113B1 (ko) * 2002-02-14 2010-11-08 기린 홀딩스 가부시키가이샤 지질대사 개선용 조성물 및 식품
WO2004037180A2 (en) * 2002-10-21 2004-05-06 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
WO2005039483A2 (en) * 2003-05-22 2005-05-06 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
EP1928248A4 (en) * 2005-08-09 2009-09-16 Metaproteomics Llp MODULATION OF KINASE PROTEINS USING HOP OR ACACIA PRODUCTS
WO2007067812A2 (en) * 2005-12-09 2007-06-14 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
EP2043621A4 (en) * 2006-06-20 2009-08-26 Metaproteomics Llc TREATMENT OF CANCER BY MODULATION OF PROTEIN KINASE USING HEXAHYDRO-ISOALPHA ACIDS
US20080051466A1 (en) * 2006-06-20 2008-02-28 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment
AU2008229110A1 (en) * 2007-03-19 2008-09-25 Metaproteomics, Llc Methods and compositions for promoting bone and joint health
CA2686043A1 (en) 2007-05-11 2008-11-20 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
CN101969972A (zh) * 2007-12-10 2011-02-09 麦特普罗泰欧米克斯有限公司 癌症、血管生成、以及与其相关的炎症通路的取代的1,3-环戊二酮多靶点蛋白激酶调节剂
US20100222262A1 (en) * 2008-04-02 2010-09-02 Metaproteomics, Llc Substituted 1, 3-cyclopentadione attenuated endothelial inflammation and endothelial-monocyte interactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892808A (en) * 1965-11-17 1975-07-01 Carlton & United Breweries Hop extracts
DE1901277A1 (de) * 1969-01-10 1970-08-06 Partipharm Ag Mittel zur Kompensation uebermaessigen Zigarettenkonsums
US5370863A (en) * 1992-12-16 1994-12-06 Miller Brewing Company Oral care compositions containing hop acids and method
JPH06312924A (ja) * 1993-04-28 1994-11-08 Asahi Breweries Ltd 抗酸化作用を有するフムロン類の利用

Also Published As

Publication number Publication date
EP0677289A2 (en) 1995-10-18
US5604263A (en) 1997-02-18
CA2146820A1 (en) 1995-10-13
NO951422D0 (no) 1995-04-11
HU9501043D0 (en) 1995-06-28
EP0677289B1 (en) 1999-01-13
ES2129691T3 (es) 1999-06-16
AU696334B2 (en) 1998-09-10
EP0677289A3 (en) 1996-10-23
TW427901B (en) 2001-04-01
DE69507185T2 (de) 1999-09-09
ATE175575T1 (de) 1999-01-15
FI951702A0 (fi) 1995-04-10
DE69507185D1 (de) 1999-02-25
HUT71604A (en) 1996-01-29
FI951702A (fi) 1995-10-13
NO951422L (no) 1995-10-13
DK0677289T3 (da) 1999-09-06
AU1638495A (en) 1995-10-19

Similar Documents

Publication Publication Date Title
KR950031059A (ko) 골다공증 치료용 약제학적 조성물
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
BR0008491A (pt) Inibidores de metaloprotease de ácido hidrox mico de sulfona aromática
CA2244785A1 (en) Pentafluorobenzenesulfonamides and analogs
BR9811099A (pt) Inibidores de urocinase
BE901737A (fr) Composition pharmaceutique pour le traitement de l'ischemie myocardique aigue.
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
BR9909958A (pt) Formulação farmacêutica, respectivos processo de preparação e uso e método de tratamento ou prevenção de distúrbios ósseos
ES2128051T3 (es) Isomero de doble enlace de la equilina, procedente de la isomerizacion acida de la equilina.
ATE386523T1 (de) Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes
NO20002548D0 (no) Nye substituerte dimere forbindelser, en fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger som inneholder dem
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
ES2132383T3 (es) Inhibidores de proteasa hiv.
ES2188908T3 (es) Derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes relacionados con el estrogenos.
KR970701044A (ko) 콜린에스테라제 활성제
DE69011130T2 (de) Pharmazeutische zusammensetzung bestimmt zur behandlung oder vorbeugung von retroviralen infektionen.
ES2188909T3 (es) Nuevos derivados de cis-3,4-cromano utiles para la prevencion o tratamiento de sindromes o enfermedades relacionados con el estrogeno. os
NO986041L (no) FremgangsmÕte ved behandling av plantesykdom
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
KR880009644A (ko) 궤양성 대장질환 치료용 약한 조성물
DK1662007T3 (da) Forebyggende middel eller lægemiddel til inflammatoriske tarmsygdomme indeholdende anti-CD81-antistof som den aktive bestanddel
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
ES2078305T3 (es) 2-alquil-3-benzoilbenzofuranos utiles para el tratamiento de la arritmia cardiaca.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid